- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953482
Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
Anaphylaxis is a hypersensitivity reaction systemic, generalized, severe, life-threatening that may result from exposure to a triggering factor. The prevalence of anaphylaxis is 0.05 to 2% in the general population. Most reactions appear within 30 minutes after contact with the triggering factor and last up to 6 hours. The main triggering factors are: 1/food, 2/hymenopteran bites, 3/drugs. The main treatment is the early administration of adrenaline by Intramuscular route on medical prescription or by AAI (adrenaline auto-injector) associated with the exclusion of the allergen. Adrenaline treatment should be administered as soon as possible, a failure or delay in the use of adrenaline is a risk factor for death. Anaphylaxis is a chronic disease and the patient must be informed from the first episode about the risk of recurrence and the risk of death he is exposed to. Patient education is essential for the complete removal of the triggering factor, recognition of anaphylaxis symptoms and use of AAI. The risk of recurrence is high given the difficulty to completely eliminate the favourable factor (mainly food causes and hymenopteran bites): 1/3 of deaths from food anaphylaxis occur at home, and the peak mortality rate is between 10 and 30 years old. The diagnosis of anaphylaxis can be difficult because the symptomatology can be so varied. It is under-diagnosed, which leads to a lack of medical care and therefore an under-prescription of AAI. Some American studies identifying emergency room visits for anaphylaxis find that in less than 30% of cases there is a prescription for AAI, in less than 40% of advices about triggering factor's eviction and in less than 20% a guidance to an allergology consultation. In France, the HAS published in 2013 a procedure to be followed after the treatment of a suspected anaphylaxis: the patient's management must be diagnostic, therapeutic and educational. It must be systematically based on three axes:
- the prescription of AAI with an explanation of its use,
- the provision of written information on the mechanism and symptoms of anaphylaxis, attitude to be followed in event of an anaphylactic reaction, and need for eviction if the allergen has been identified,
- guidance to an allergology consultation.
Therapeutic education for anaphylactic patients is essential given the risk involved. In an American study, it was shown that only 60% of teens and young adults suffering from food allergies report having AAI systematically with them. Information and education is therefore essential for these patients.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- Maison de santé porte de Vanves
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe Hospitalier Paris Saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient whose age ≥ 18 years
- Francophone patient
- Patient not opposing his participation in the research protocol
- Patient with a history of an anaphylactic reaction
Exclusion Criteria:
- Patient under tutorship or curatorship
- Patient deprived of liberty
- Patient presenting an allergic reaction or an anaphylaxis
- For patients presenting to emergencies at Groupe Hospitalier Paris Saint-Joseph (GHPSJ) : Unstable health estate (gravity criteria hemodynamic, respiratory or neurological and any pathologies with a severity that do not allow the questionnaire to be answered).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient's medical management after a first episode of anaphylaxis
Time Frame: Day 0
|
Percentage of patients who had management with:
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient's knowledge of attitude to have with anaphylaxis
Time Frame: Day0
|
Percentage of correct answers to the study-specific questionnaire related to knowledge of attitude to have with a new anaphylactic reaction.
|
Day0
|
Collaborators and Investigators
Investigators
- Study Director: Eloïse P TRABATTONI, MD, Groupe Hospitalier Paris Saint Joseph
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREVANA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaphylaxis
-
National Institute of Allergy and Infectious Diseases...RecruitingIdiopathic Anaphylaxis | Drug Anaphylaxis | Venom Anaphylaxis | Food AnaphylaxisUnited States
-
University of MichiganThe Gerber FoundationRecruiting
-
Central Hospital, Nancy, FranceSanofi; GlaxoSmithKline; Zambon SpA; Laboratoires URGO; Pierre Fabre Medicament; Bi... and other collaboratorsUnknownNeuromuscular Blocking Agents AnaphylaxisFrance
-
University of LeedsUnknownExercise AnaphylaxisUnited Kingdom
-
University Hospital, AngersRecruitingAnaphylaxis Caused by Hymenoptera Venom (Disorder)France
-
Mahidol UniversityCompletedWheat Allergy | Anaphylaxis Food | Anaphylaxis ExerciseThailand
-
Ann & Robert H Lurie Children's Hospital of ChicagoNorthwestern University Feinberg School of MedicineCompleted
-
Massachusetts General HospitalWithdrawnAnaphylaxis as a Result of Allergen or Venom ImmunotherapyUnited States
-
Aravax Pty LtdRecruitingImmune System Diseases | Peanut Hypersensitivity | Peanut Allergy | Peanut-Induced AnaphylaxisUnited States, Australia
-
Merck Sharp & Dohme LLCCompleted